New Jersey-based PuraCap Pharmaceutical LLC recently announced the acquisition of Blu Pharmaceutical LLC and Blu Caribe Inc., creating PuraCap International LLC, a joint venture between PuraCap and Dangdai International Group Co., Ltd.
This acquisition will expand PuraCap’s manufacturing expertise beyond soft gelatin capsules to include oral tablet and capsule dosage forms for both the U.S. and global markets.
The acquisition includes a state-of-the-art 145,000 sq. ft. FDA approved, cGMP compliant manufacturing facility in Dorado, as well as an 185,000 square-foot warehouse and distribution center in Franklin, Kentucky.
Under PuraCap International LLC, the newly created company will grow and strengthen PuraCap’s considerable manufacturing capabilities over the next several years, according to PuraCap Pharmaceutical CEO Dahai Guo.
“This acquisition is a major step in the growth of our capability in the manufacturing of oral solid dosage forms in the United States, which complements our state-of-the-art soft gelatin capsule manufacturing facility in Wuhan, China,” said Guo.
“Dangdai International Group Co., Ltd is especially pleased to be part of this joint venture that broadens our investment activity into the western hemisphere in a company poised for strong growth,” said Hansheng Zhou, CEO of Wuhan Dangdai Science & Technology Industries Group Co., Ltd.
Dangdai International Group Co. Ltd. is a wholly owned subsidiary of Wuhan Dangdai Science & Technology Industries (Group) Co. Ltd., a conglomerate with a substantial medical and pharmaceutical portfolio in China.
“This acquisition brings us further infrastructure and sales channels, not only in the retail generic drug business, but also the U.S. government purchasing tender business channel to help meet the growing demand for generic prescription products,” said Sean Weeks, President of PuraCap International LLC.